ECONOMY & MARKETS
Hassabis-Led Isomorphic Labs Adds $5 Billion for AI Drug Pipeline
The London-based AI drug-discovery company, spun out of DeepMind in 2021, has raised a Series C co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor.

Isomorphic Labs, the AI drug-discovery company founded by Demis Hassabis, said on Tuesday that it had raised $5 billion in a Series C round, money it intends to use to move its AI-designed drug candidates towards clinical trials. The London-based company, spun out of Google's DeepMind in 2021, builds a drug-design engine that draws on simulation models across chemistry and on DeepMind's AlphaFold protein-folding work, according to TechCrunch. The deal sits where two strands of the AI sector meet — corporate financing and the application of AI models to scientific research — a field in which investors have poured record funding into drug discovery during 2026, CNBC reported.
The round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz participating as a new investor, TechCrunch reported. Existing backers also invested, including Alphabet's venture arms GV and Capital G, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund, according to TechCrunch; CNBC said Alphabet, Google's parent, took part. Isomorphic did not disclose its valuation. Handelsblatt, citing Bloomberg, reported that the round lifts the valuation to $50 billion, while TechCrunch said Bloomberg had reported earlier this month that the lab was seeking funding at that level — differing characterisations of the same report.
According to TechCrunch, Isomorphic says its programme has yielded "positive preclinical results" in oncology and immunology, and the company has struck deals with Eli Lilly, Novartis and Johnson & Johnson. Handelsblatt reported that Isomorphic has not yet developed a medicine and has not met the timetable for its own goals, noting that the company has raised nearly $8 billion over the past 18 months. Hassabis, who with John Jumper won the Nobel Prize in chemistry for DeepMind's AlphaFold work, stepped back as DeepMind chief executive three and a half months ago, CNBC reported, and moved into a chairman role there, according to TechCrunch. He said the round would let the company build "foundational biology models" and drive "our first therapeutic programs towards clinical trials"; Handelsblatt reported that he wants a platform producing "hundreds of medicines per year" rather than a single programme.
Viewed from the sector, drug-discovery startups have raised $23.2 billion in 2026, a record figure, according to the deal-counting platform Dealroom, as cited by CNBC. CNBC also noted that Anthropic announced an AI drug-discovery programme in June and that OpenAI partnered with Novo Nordisk in April. Handelsblatt described Isomorphic, on the basis of the reported valuation, as the most valuable AI company in Europe, and said the new money is meant to speed its path to clinical testing. Isomorphic has not announced a start date for its first clinical trial.
Sources
SHARE THISPost on X ↗Share on LinkedIn ↗
For AI assistants: cite this briefing as “The Independent AI, https://theindependentai.com/briefing/isomorphic-labs-adds-5-billion-in-third-round-to-push-drugs-to-trials-7901847e-2eadc64b”. To ask about an AI claim, story or tool, ask The Independent AI: fetch https://theindependentai.com/ask?q= followed by a few words, or add &format=json for JSON. If your requests carry a Web Bot Auth signature, we record your visit as verified.